

2025 #34

November 3, 2025

INSIDE:

WORD IN WASHINGTON	2
STATE ADVOCACY BRIEFS	3
ABC Executive Fellows Program Call for Applicants Closes on November 7 th	4
Time Is Running Out: Register for the <i>Rise & Lead Workshop</i> November 13 th -14 th	4
ABC Board of Directors Call for Nominations is Open	4
Workforce Trends Survey Report Available	5
Save the Date: 2026 ABC & ADRP Meetings and Workshops	5
Input Requested: ADRP Member Satisfaction Survey	5
2025 International Showcase Takes Place on November 12 th	5
BRIEFLY NOTED	6
MEMBER NEWS	6
GLOBAL NEWS	7
COMPANY NEWS	7
CALENDAR	8
POSITIONS	9

Clinical Practice Guideline Published in *CHEST* Recommends Restrictive Transfusion Strategy in Critically Ill Patients

An expert panel from the American College of Chest Physicians have developed and [published](#) a guideline regarding red blood cell (RBC) transfusions in critically ill patients. According to the authors of the paper that appears in *CHEST*, the panel consisted of, “cochairs [who] nominated a diverse and multidisciplinary panel based on their expertise encompassing critical care medicine, cardiology, hematology, and gastroenterology, and hepatology. The final panel [included] the two guideline co-chairs, nine panelists, two methodologists, one medical librarian, and one liaison to American College of Chest Physicians Guidelines Oversight Committee. [Recommendations were] drafted using the Grading of Recommendations, Assessment, Development, and Evaluations approach.”

The authors noted that the, “restrictive [transfusion] threshold [is] generally defined as a hemoglobin level of 7 to 8 g/dL and a permissive threshold typically rang[es] from a hemoglobin level of 8.5 to 10 g/dL. Hemodynamic instability typically has been defined as hypotension (mean arterial pressure, <65 mm Hg, or systolic BP, <100 mm Hg), tissue hypoperfusion caused by acute bleeding, or both.”

The panel performed a, “comprehensive search of MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials using relevant keywords [in] May 2021, with an updated search performed in MEDLINE in January 2024. Searches were limited to English language randomized controlled trials (RCTs), cohort studies, and case-control studies with at least 30 participants. Systematic reviews and prior guidelines were reviewed for context and completeness.”

The recommendations are:

- “[i]n critically ill patients, we recommend a restrictive RBC transfusion strategy over a permissive RBC transfusion strategy (Strong Recommendation, Moderate Certainty of Evidence);
- [i]n critically ill patients with acute gastrointestinal bleeding, we recommend a restrictive RBC transfusion strategy over a permissive RBC transfusion strategy (Strong Recommendation, Moderate Certainty of Evidence);
- [i]n critically ill patients with acute coronary syndrome, we suggest against a restrictive RBC transfusion strategy (Conditional Recommendation, Low Certainty of Evidence);

(continued on page 2)

Clinical Practice Guideline Published in CHEST Recommends Restrictive Transfusion Strategy in Critically Ill Patients (continued from page 1)

- [i]n critically ill patients undergoing cardiac surgery, we suggest a restrictive RBC transfusion strategy over a permissive RBC transfusion strategy during the perioperative period (Conditional Recommendation, Moderate Certainty of Evidence);
- [i]n critically ill patients with isolated elevation of serum troponin without other evidence of cardiac ischemia, we suggest a restrictive RBC transfusion strategy over a permissive RBC transfusion strategy (Conditional Recommendation, Very Low Certainty of Evidence); and
- [i]n patients with septic shock and end-organ hypoperfusion, we suggest against adding permissive RBC transfusion thresholds to usual care (Conditional Recommendation, Low Certainty of Evidence)."

Limitations of the guideline acknowledged by the panel include, "the quality of the evidence, which ranged from moderate to very low. For conditions like acute coronary syndrome and septic shock, the number of studies was small, and the inferences were not strong. No studies specifically addressed critically ill patients with elevated troponin levels. Moreover, the studies did not assess additional aspects of the transfusion process (storage age, donor characteristics, processing, storage solutions). These guidelines provide an opportunity for institutions to develop local policies, monitor their impact on transfusion practices, and to create a framework to longitudinally optimize RBC use."

Citation: Coz Yataco, A.O., Soghier, I., Hébert, P.C., *et al.* "[Red Blood Cell Transfusion in Critically Ill Adults: An American College of Chest Physicians Clinical Practice Guideline.](#)" *CHEST*. 2025.

WORD IN WASHINGTON

America's Blood Centers (ABC) joined more than 70 organizations on a [letter](#) sent to congressional leaders in the House of Representatives encouraging the U.S. House Energy and Commerce Subcommittee on Health to include the Sickle Cell Disease (SCD) Comprehensive Care Act ([S. 721/H.R. 5178](#)) in, "an upcoming hearing markup." The coalition letter explained that, "the Sickle Cell Disease Comprehensive Care Act authorizes state Medicaid programs to provide comprehensive, coordinated care through a health home model for individuals with SCD based on their SCD status alone. The health home model is a proven care delivery model in Medicaid that has been widely used by states to improve quality, enhance care, and reduce unnecessary costs. Health homes for SCD will help to alleviate the many challenges and disparities in care that individuals with SCD have faced for far too long. This bill ensures a

(continued on page 3)

The *ABC Newsletter* (ISSN #1092-0412) is published by America's Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2025 by America's Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher (ABC members need not obtain prior permission if proper credit is given).

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognizes the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies, and programs that increase awareness about the need for blood donation; and serve as a thought leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

America's Blood Centers

Chief Executive Officer: Kate Fry

Chief Medical Officer: Jed Gorlin

Editor: Mack Benton

Subscriptions Manager: Leslie Maundy

Annual Subscription Rate: \$420

Send subscription queries to

memberservices@americasblood.org

America's Blood Centers

1717 K St. NW, Suite 900, Washington, DC 20006

Phone: (202) 393-5725

Send news tips to newsletter@americasblood.org.

WORD IN WASHINGTON (continued from page 2)

multi-faceted approach to care, ensuring SCD patients have access to coordinated clinical, mental health, and ancillary services to address their physical, mental, and social needs. [In addition to improving care,] the bill would also save money in the Medicaid program. We are pleased to let you know that the Congressional Budget Office scored the legislation as saving \$4 million in the 10-year budget window. Together, we have an opportunity to profoundly impact care for people living with SCD on Medicaid. Adopting SCD as an eligible condition for health homes will change the care paradigm for impacted individuals and save our health care system millions of dollars, while providing a better quality of life for a very under-represented patient population. We strongly urge you to prioritize the Sickle Cell Disease Comprehensive Care Act in the Subcommittee's upcoming deliberations."

(Source: Coalition [Letter](#), 10/29/25)

The *Associated Press* is reporting that the U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) Director George Francis Tidmarsh, MD, PhD has [resigned in the wake of a review into, "serious concerns about his personal conduct."](#) Dr. Tidmarsh was [named](#) to the role in July and also briefly served as acting director of the Center for Biologics Evaluation and Research (CBER) following the temporary departure of CBER Director Vinay Prasad, MD, MPH. According to his bio, "Dr. Tidmarsh brought over 30 years of experience in biotechnology, clinical medicine, and regulatory science [to FDA] and joined the FDA from Stanford University's School of Medicine where he was adjunct professor [of] Pediatrics and Neonatology." U.S. Health and Human Services (HHS) Press Secretary Emily Hilliard told the *Associated Press* in an email, "Secretary Kennedy expects the highest ethical standards from all individuals serving under his leadership and remains committed to full transparency."

(Source: *Associated Press*, "[FDA's top drug regulator resigns after federal officials probe 'serious concerns' about his conduct](#)," 11/3/25)

Alicia Jackson, PhD has been [named](#) director of the Advanced Research Projects Agency for Health (ARPA-H). According to a report from *ExecutiveGov*, "Dr. Jackson had a previous stint at the Department of Defense (DoD) [and] will lead [the] agency tasked with accelerating research and development of cutting-edge health projects. [She] founded and most recently served as chief executive officer of Evernow, a telehealth firm specializing in women's healthcare. [Before working in the private sector,] Dr. Jackson served for over one year as deputy director of the biotechnology office at DOD's Defense Advanced Research Projects Agency. She previously held for more than three years the role of program manager for the agency's \$200 million portfolio of projects — that she established — in synthetic biology and unconventional electronic devices. [She] holds a PhD in materials science and engineering, nanotechnology, from the Massachusetts Institute of Technology. [Dr. Jackson replaces] Jason Roos, who was serving as acting director."

(Sources: HHS [Website](#), 10/23/25; *ExecutiveGov*, "[Health Tech Expert Alicia Jackson to Lead ARPA-H](#)," 10/23/25) 💧

STATE ADVOCACY BRIEFS

The Pennsylvania State House of Representatives has introduced [House Bill \(H.B.\) 1997](#). The proposed legislation would require a health care facility to, "allow an individual on whom a medical procedure is to be performed an autologous blood transfusion or direct allogeneic blood transfusion for the medical procedure [if the individual] notifies the health care facility of the intention to provide an autologous blood transfusion or direct allogeneic transfusion [and] for a direct allogeneic blood transfusion, provides a list of eligible blood donors."

(Source: [H.B. 1997](#), 10/27/25) 💧



America's Blood Centers®
It's About *Life*.

INSIDE ABC

The programs and services described in the Inside ABC section are available to ABC member blood centers and their staffs only, unless otherwise specified.

ABC Executive Fellows Program Call for Applicants Closes on November 7th

[Apply](#) to participate in the 2026 [ABC Executive Fellows Program \(EFP\)](#) by the November 7th deadline. America's Blood Centers (ABC) is partnering with Vanderbilt University's Owen School of Management. This groundbreaking initiative offers industry-specific, best-in-class leadership training to blood community executives, elevating individuals, organizations, and the nation's blood supply. The program will accept an annual cohort of up to 25 fellows who will participate in:



- “a week-long leadership residency at Vanderbilt;
- three additional in-person learning immersions;
- virtual seminars taught by Vanderbilt faculty;
- a 360-leadership assessment;
- individual executive coaching; and
- a capstone project presented at ABC Annual Meeting 2027.

The EFP strives to accept participants from a wide variety of backgrounds and leadership roles. Final selections for the 2026 cohort will occur by December 2025. An independent selection committee is responsible for choosing each year's cohort. Senior leaders from ABC member blood centers, hospital-associate members, affiliate organizations, and industry partners are encouraged to apply. The Foundation for America's Blood Centers (FABC) is pleased to announce up to \$20,000 in partial scholarships for individuals employed by ABC active member blood centers. Additional information regarding tuition rates is available [here](#).

Time Is Running Out: Register for the *Rise & Lead Workshop* November 13th-14th

Rise & Lead
A WOMEN'S LEADERSHIP WORKSHOP

[Registration](#) is open for the ABC 2025 ABC Women's Executive Leadership Community (WELC) [Rise & Lead Workshop](#) taking place November 13th-14th in San Antonio, Texas at the Westin Riverwalk. Check out the [schedule](#) as this workshop is designed for women in leadership positions, emerging leaders, and professionals seeking personal and career growth. It also welcomes individuals who want to cultivate diverse perspectives. Attendees will engage in an intimate, engaging, and interactive environment focused on networking, mentorship, and meaningful discussions on leadership and growth. Please [contact us](#) with questions.

ABC Board of Directors Call for Nominations is Open

ABC is currently accepting [nominations](#) for the ABC Board of Directors for terms starting April 1st, 2026. Individuals may self-nominate or nominate other ABC members by Friday, November 14th. Please [contact us](#) with questions.

(continued on page 5)



INSIDE ABC (continued from 4)

Workforce Trends Survey Report Available

ABC has published the [2025 Workforce Trends Survey Report](#). This resource offers deep insights into compensation, benefits, human resources policies, turnover and retention rates, and workforce trends specific to blood centers. Those ABC member blood centers who participated in the Workforce Trends Survey can purchase the report at a discounted price (code required and has been emailed to authorized individuals) of \$450 while non-participating blood centers can purchase the report at the full price of \$900. This survey combines the previous Compensation & Benefits and Employee Turnover & Retention surveys. Please [contact us](#) with questions.

Save the Date: 2026 ABC & ADRP Meetings and Workshops

ABC has announced the 2026 ABC & ADRP Meetings and Workshops. Events include:

- ABC Annual Meeting – March 9-12, 2026; Tucson, Ariz.;
- ADRP Annual Conference – May 14-16, 2026; Minneapolis, Minn.;
- ABC Advocacy Workshop – June 8-9, 2026; Washington, D.C.;
- ABC WELC Rise & Lead Workshop – Fall 2026; and
- ADRP Master Class Workshop – Fall 2026.

We can't wait to welcome you in 2026! Please [contact us](#) with questions.

Input Requested: ADRP Member Satisfaction Survey

Take part in shaping the future of ADRP by completing the [ADRP Member Satisfaction Survey](#)! We encourage all ADRP members to participate as this is your opportunity to let your voice be heard, as your input will help shape our strategic priorities for the next three years. ADRP values and welcomes all member feedback and asks you to please complete the survey by Tuesday, November 11th. If you have any questions or have trouble accessing the survey, please [contact us](#).

2025 International Showcase Takes Place on November 12th

[Registration](#) is open for the [2025 ADRP International Showcase](#) and complimentary for all blood center staff! This virtual event will take place on Wednesday, November 12th at 1 p.m. EST and includes blood community professionals worldwide taking part in our annual forum to share, connect, and learn from each other! A recording of this event will be made available to all registrants. Hear speakers such as Pilar Cordoba, director of Marketing and Communications at Banc de Sang i Teixits in Catalonia, Spain presenting "*From Pixels to Purpose: Augmented Reality as a Game-changer for Blood Donation in Catalonia*." This presentation will highlight how an innovative campaign used augmented reality (AR) to boost blood donation during a traditionally low-donation period. By combining technology with Catalonia's cultural symbol of human towers, the initiative redefined blood donation as a collective act of solidarity integrating AR experiences, digital channels, and street activations to engage donors emotionally and visually. The result? Increased donor participation, stronger social engagement, and a lasting sense of belonging among participants. Additional topics and speakers this year include:

- "*The Making of a Customer Service Program*" by Catherine Boisvert, Advisor of Customer Experience at Héma-Québec;
- "*Using Social Media to Enhance PR*" by Jennifer Wilson, Head of Donor Marketing and Engagement at the Scottish National Blood Transfusion Service; and
- "*How to Start Working on the Plasma Donor Journey?*" by Michele Barth, National Manager of Donor Experience at the French Blood Establishment (EFS). 💧



BRIEFLY NOTED

The University of Minnesota's Center for Infectious Disease Research and Policy (CIDRAP) and *The New England Journal of Medicine* (NEJM) are [collaborating](#) to develop, "a new publication to report on outbreaks and emerging diseases," [according](#) to from *Becker's Clinical Leadership*. The publication will be named *Public Health Alerts* and is set, "to launch within the next month. It will serve as an alternative to the U.S. Centers for Disease Control and Prevention's *Morbidity & Mortality Weekly Report* (MMWR), which has been paused due to the federal government shutdown. [A joint editorial team from] CIDRAP and NEJM will lead the effort, which aims to ensure timely communication of urgent public health information." Michael Osterholm, PhD, director of CIDRAP, "[announced](#) the publication during opening remarks at 'IDWeek,' a joint annual meeting of several infectious diseases associations. 'It will be a way to convey the information that once was shared in the MMWR with all of us in a very timely way,'" Dr. Osterholm said according to *Becker's Clinical Leadership*. "We encourage all of you to begin thinking about submissions about outbreaks [and] data you think should be evaluated."

(Source: *Becker's Clinical Leadership*, "[Experts create alternative to weekly CDC reports](#)," 10/22/25)

The Cybersecurity & Infrastructure Security Agency (CISA), National Security Agency (NSA), and international cybersecurity partners have [collaborated](#) to release a new guidance on "[Microsoft Exchange Server Security Best Practices](#)." The announcement explained that the guide is meant to, "help network defenders harden on-premises Exchange servers against exploitation by malicious actors. Threat activity targeting Exchange continues to persist, and organizations with unprotected or misconfigured Exchange servers remain at high risk of compromise. Best practices in this guide focus on hardening user authentication and access, ensuring strong network encryption, and minimizing application attack surfaces. CISA recommends organizations also decommission any remaining end-of-life on-premises or hybrid Exchange servers after transitioning to Microsoft 365, as retaining the 'last Exchange server' can expose organizations to ongoing exploitation activity."

(Source: CISA [Announcement](#), 10/30/25) 💧

MEMBER NEWS

Versiti Blood Center of Ohio is [celebrating](#) its 60th anniversary this week. According to WHIO TV-7, festivities will take place all week as the organization's, "Dayton Donor Center highlights Versiti Blood Center of Ohio's commitment to community and the vital role of blood donation in saving lives."

(Source: WHIO TV-7, "[Blood center to hold 60th anniversary celebration this week in Downtown Dayton](#)," 11/2/25)

LifeSouth Community Blood Centers has [announced](#) the opening of a 2nd donor center in Montgomery, Ala. LifeSouth Vice President of Operations Sharon Carpenter told WAKA Action 8 News, "[i]t adds a resource to our ability to collect donors. So, it makes our job easier when we have more donors because we have more blood products for the hospital." The donor center is expected to, "make it easier for people on the east side of Montgomery to donate."

(Source: WAKA Action 8 News, "[LifeSouth opens second blood center in Montgomery](#)," 10/10/25) 💧





GLOBAL NEWS

The World Health Organization (WHO) recently [added](#) an, “isolate of Middle East respiratory syndrome coronavirus (MERS-CoV), one of three high-impact coronaviruses with pandemic potential to the [WHO BioHub System](#).” The WHO noted that BioHub allows countries the opportunity to, “voluntarily share and request biological materials with epidemic or pandemic potential. This initiative, set up by the Director-General of WHO during the COVID-19 pandemic, directly supports pathogen characterization and research, surveillance and risk assessments, and in the future will contribute to the development of medical countermeasures such as diagnostics, vaccines, and therapeutics by enabling rapid access to verified biological materials and data essential for advancing research, validation, and product development. MERS-CoV is a zoonotic virus and can be transmitted between dromedary camels and humans. Infection in people may lead to acute respiratory disease and even death, with a fatal outcome in 37 percent of cases reported to date. [Currently no licensed vaccines or therapeutics against MERS exist.]” There are no reported cases of MERS-CoV transmission via blood transfusion nor any other coronavirus.

(Source: WHO [Announcement](#), 10/23/25)

The South African National Blood Service (SANBS) has [launched](#) the *Blood Matters* podcast. According to a SANBS news release, the episodes will feature, “real, unfiltered conversations about what truly matters. From unpacking everyday ethical dilemmas and the human stories behind blood donation, to exploring how trust and compassion flow through communities, the podcast goes deeper than blood. [The podcast intends to blend] insight, hum[o]r, and humanity spotlighting the heartbeat of South Africa’s generosity while tackling themes that shape the SANBS journey: accountability, transparency, service, and social good.”

(Source: SANBS [News Release](#), 10/27/25)

A [report](#) from the *Times of India* described a tainted blood investigation in India for government hospitals in Jharkhand. The publication explained that, “six children with thalass[e]mia tested HIV positive following transfusions at a government hospital whose blood bank had been operating without a valid license since 2023.” The blood center has now started using, “the more rigorous ELISA test (Enzyme-Linked Immunosorbent Assay) for HIV detection. [In 2018, seven children] contracted HIV from transfused blood.”

(Source: *Times of India*, “[6th child tests HIV+ in Jharkhand amid crackdown on healthcare system](#),” 11/3/25)



COMPANY NEWS

BBG Advanced Therapies has [announced](#) the, “world’s only mobile leukapheresis center recorded its first cell donation [on October 20th.]” According to a company news release, “the mobile leukapheresis center includes two cell collection stations and a testing laboratory. [Just a handful of fixed-site centers in Texas] are equipped to collect immune cells, and they are concentrated in the state’s major metropolitan areas. The mobile leukapheresis center will widen the scope of these new advanced therapies and strengthen the healthcare ecosystem in San Antonio and South Texas.” Adrienne Mendoza, chief operating officer at BBG Advanced Therapies, added in the news release, “[i]n a region the size of South Texas,



(continued on page 8)

COMPANY NEWS (continued from 7)

providing patient or donor access to these kinds of lifesaving therapies can be difficult. We believe that bringing this option to our service area can help make cutting-edge healthcare available to [many] more patients who need it — and serve as a model for delivering therapies not only in the U.S., but around the world. [Just like our blood bus] in 1974 brought donation opportunities into the community, this vehicle brings cell collections directly to patients.”

(Source: BBG Advanced Therapies [News Release](#), 10/22/25)

The U.S. Food and Drug Administration (FDA) has [granted](#) 510(k) clearance to **Roche Diagnostics** for the cobas pro serology solution applicable to the Elecsys Syphilis and Elecsys Anti-CMV. According to an approval letter from the agency, the cobas pro serology solution, “is a combination of the cobas pro serology controller, cobas pro integrated solutions (cobas e 801 analytical units only) and applicable licensed blood screening assays. The system automates electrochemiluminescence immunoassay test processing, result interpretation, and data management functions for screening of donations of whole blood and blood components using plasma or serum samples.” Elecsys Syphilis is, “an *in vitro* immunoassay for the qualitative detection of total antibodies (IgG and IgM) to *Treponema pallidum* in human serum and plasma.” The FDA letter described the Elecsys Anti-CMV as an, “*in vitro* immunoassay for the qualitative detection of antibodies to Cytomegalovirus in human serum and plasma.”

(Source: FDA [Letter](#), 10/9/25)

Terumo Blood and Cell Technologies (Terumo BCT) recently [announced](#) that, “The Blood Center (New Orleans, La.) has become the second U.S. blood center to implement the Terumo BCT Reveos™ Automated Blood Processing System and the Lumia™ Software Platform.” A company news release explained that, “Reveos is the only whole blood automation system available in the U.S. that separates whole blood into platelets, plasma, and red blood cells in a single fully automated centrifugation cycle.” Mickie Wilson-Martin, manager of Production and Distribution at The Blood Center, stated in the news release, “[t]his is a milestone moment for our center. We’ve waited a long time for a solution like this — one that truly modernizes how we manage whole blood. Being among the first in the U.S. to implement Reveos is something we’re incredibly proud of, and it sends a powerful message as we work to attract younger talent. We may be small, but we are mighty, and we’re here for our community.”

(Source: Terumo BCT [News Release](#), 10/22/25) 💧

CALENDAR

Note to subscribers: Submissions for a free listing in this calendar (published weekly) are welcome. Send information to newsletter@americasblood.org. (For a more detailed announcement in the weekly “Meetings” section of the newsletter, please include program information.)

2025

Nov. 6-7. **National Institutes of Health’s (NIH) National Heart, Lung, and Blood Institute (NHLBI) Cardiopulmonary Complications of Hematopoietic Stem Cell Transplantation (HCT) and Gene Therapy Workshop (Hybrid).** [Registration](#) is open. More information is available [here](#).

Nov. 12. **2025 ADRP International Showcase.** [Registration](#) is open. More information is available [here](#).

Nov. 13-14. **2025 America’s Blood Centers (ABC) Women’s Executive Leadership Community (WELC) Rise & Lead Workshop.** [Registration](#) is open. More information available [here](#).

(continued on page 9)

CALENDAR (continued from 8)

Nov. 17-20. **American Society for Clinical Pathology (ASCP) Annual Meeting. Atlanta, Ga.** [Registration](#) is open. More information available [here](#).

2026

Feb. 11-12. **4th Biennial International Plasma and Fractionation Association (IPFA) & EBA Symposium on Plasma Collection and Supply. Leuven, Belgium.** [Registration](#) is open. More information is available [here](#).

Mar. 9-12. **2026 ABC Annual Meeting. Tucson, Ariz.** More information is coming soon.

May 12-14. **2026 ADRP Annual Conference. Minneapolis, Minn.** More information is coming soon.

June 8-9. **2026 ABC Advocacy Workshop. Washington, D.C.** More information is coming soon.

Oct. 4-7. **American Association of Tissue Banks (AATB) Annual Meeting. San Francisco, Calif.** More information available [here](#).

Oct. 17-19. **Association for the Advancement of Blood & Biotherapies (AABB) Annual Meeting. Atlanta, Ga.** More information is coming soon. ♦

CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC members. There are charges for non-members: \$139 per placement for ABC Newsletter subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: newsletter@americasblood.org

POSITIONS

Medical Laboratory Scientist – Transfusion Services (ARUP Laboratories, Salt Lake City, UT). ARUP Laboratories is seeking two Medical Laboratory Scientists to join our Transfusion Services team. Our Transfusion team is dedicated to delivering exceptional patient care by meeting the transfusion needs of University of Utah Hospitals and Clinics, as well as Huntsman Cancer Institute. Our mission is to ensure the right blood product reaches the right patient, at the right time, for the right reason. As a Level 1 trauma center, the University of Utah Hospital also provides solid organ and bone marrow transplants and serves as the burn center for the Mountain West. Our testing capabilities include type and screens, crossmatches, antibody identification using both manual and automated methods, and neonatal testing. This department offers a dynamic and fast-paced environment with diverse immunohematology experiences. Team members collaborate closely with residents, medical directors, and patient care teams and work in close proximity to patients. Schedules we have open are: - On/7-Off B week 10:00 PM – 8:30 AM & 7-On/7-Off A week 8:00 PM – 6:30 AM with training schedule of Monday – Friday, 8:00 AM – 4:30 PM. Posting numbers are: MEDIC01276 & MEDIC021408 located on our careers page at www.aruplab.com/careers.

our Immunohematology Reference Lab in Ft. Lauderdale, Florida. This position will perform basic through advanced serologic testing on patient and/or donor samples and interpret results in accordance with regulatory guidelines and organizational policies and procedures. Applicants must have a bachelor's degree in a biological science or related scientific field from an accredited college or university or an equivalent combination of education, certification, training, and/or experience. Applicants must also have a valid and current Florida Clinical Laboratory Technologist license, or eligible, in Immunohematology or Blood Banking. To apply and view a complete Job Description of these positions, go to Inc. www.oneblood.org and click on the Careers tab.

Quality Supervisor: Blood Bank and Transfusion Services (ARUP Laboratories, Salt Lake City, UT). ARUP Laboratories is seeking a results-driven Quality Supervisor to lead quality initiatives and provide regulatory expertise within our Donor Services. As a national nonprofit and academic reference laboratory, ARUP is at the forefront of diagnostic medicine. We are FDA, CAP-, CLIA-, and ISO 15189-certified, with over 40 years of experience delivering exceptional quality and service.

(continued on page 10)

Medical Technologists Needed for IRL! OneBlood is currently recruiting for Medical Technologists to work in

COMPANY NEWS (continued from page 9)

This is a unique opportunity to oversee and enhance quality systems in transfusion medicine. The Quality Supervisor will drive implementation of quality processes, standardization efforts, and best practices across the division. Key Responsibilities: Lead and coordinate quality initiatives for Donor Services and Transfusion Services. Support internal and external audits, risk assessments, and continuous improvement efforts. Serve as a liaison between ARUP and University of Utah staff to address quality issues and lead CAPA (Corrective and Preventive Actions). Oversee staff development, performance management, and promotions. What We're Looking For: Strong leadership and communication skills. Experience in donor services and/or transfusion services. A passion for quality and a commitment to organizational excellence. Interested candidates can apply at <https://www.aruplab.com/careers>.

Cell Therapy Technologist (Carter BloodCare). The Cellular Therapy Technologist (CTT) participates in activities in the Cellular Therapy Laboratory. These activities include, but may not be limited to, cellular therapy (CT) processing, performing and troubleshooting quality control of reagents and equipment, participating in educational instruction of students and new employees, familiarity and full compliance with all CT and general laboratory regulations, and participating in design and implementation of new methodology for processing CT products. A CTT ensures daily operations within the department meet and follow all established guidelines and provide excellence in service and patient care. Ability to work a flexible schedule, long and/or odd hours with little notice. Regular full-time attendance is required during normal working hours. This position requires a valid driver's license. **Education:** MT (ASCP), MLS (ASCP) or equivalent, or eligible with certification obtained within 90 days of hire. Bachelor of Science Degree in Clinical Laboratory Science, Medical Laboratory Science, Medical Technology, or a related field in laboratory science. **Experience:** Minimum of one year of experience as an MT/MLS. Equal Opportunity Employer: Disability/Veteran. Apply at www.carterbloodcare.org, click Careers & search for job Cell Therapy Tech or Cell Therapy Technologist (MLS).

Manager of Product Quality Control (Carter BloodCare). The Manager of Product Quality Control will be responsible for all Product Quality Control related activities of the blood center. These activities may include, but are not limited to, equipment/instrument maintenance and quality control, product testing, review of testing results, review of donor center activities, as related to Product Quality Control testing, training, and education of Product Quality Control testing staff. The Manager will monitor budget and other administrative activities for the department, as assigned by the Technical Director. Additionally, the position will be actively involved in

strategic planning and collaborating with other blood centers on projects and other corporate initiatives. The Manager will report to the Technical Director. Regular full-time attendance is required during normal working hours. **Education:** Bachelor of Science Degree, or related field. MT (ASCP), MLS (ASCP) or equivalent. **Experience:** Minimum three (3) years general laboratory experience required. Minimum one (1) year of blood banking, required. Minimum one (1) year of supervisory experience, preferred. Previous management experience, preferred. Equal Opportunity Employer: Disability/Veteran. Apply at www.carterbloodcare.org, click Careers & search for job Manager of Product Quality Control (MLS).

Senior Manager of Technical Operations (Carter BloodCare). The Senior Manager of Technical Operations (SMT) provides leadership and oversight across Distribution/Hospital Services, Product Quality Control (PQC), Component Production, and Testing and Labeling departments in North, East, and Central Texas. The SMT serves as a key operational leader with delegated authority from the Technical Director, ensuring continuity of operations, consistency of processes, and compliance with all regulatory standards. The SMT directly supervises managers across all departments and locations, guiding daily operations, hiring, and developing staff, managing training programs, and ensuring high performance standards. In partnership with the Technical Director, the SMT leads the implementation of departmental procedures, validations, and regulatory requirements. Periodic travel between assigned work areas in North, East and Central Texas is required. **Education:** Bachelor of Science Degree or related field. MT (ASCP), MLS (ASCP) or equivalent. **Experience:** Minimum of four (4) years of experience in blood bank management or supervisory position with an emphasis on inventory management and hospital services. Equal Opportunity Employer: Disability/Veteran. Apply at www.carterbloodcare.org, click Careers & search for job Senior Manager of Technical Operations (MLS).

Director of Laboratory and Technical Services. The Blood Bank of Alaska is looking for a Director of Laboratory and Technical Services. The Director of Laboratory and Technical Services is responsible for ensuring alignment of organizational goals and compliance with regulatory guidelines within the laboratory environment. This position participates as a member of the blood bank's management team in planning, program formulation, and decision making with reference to the role, functions and technical support of the blood collection and processing operations throughout the Blood Bank of Alaska. Ensures all procedures are followed and promotes a positive work environment. This position is full-

(continued on page 11)

COMPANY NEWS (continued from page 10)

time exempt. The Blood Bank of Alaska offers competitive wages and an exceptional benefits plan. We offer medical, dental, vision, life, and short/long-term disability programs to qualified employees. Paid time off (PTO), paid sick leave (PSL), holidays and a 401 (k) program are also available. The Blood Bank is an equal opportunity employer. Qualified applicants are considered for employment without regard to race, color, religion, national origin, age, disability, marital/veteran status, or any other legally protected status. Interested candidates can please apply online at: <https://bloodbankofalaska.apscareerportal.com>. A complete job description can be found there as well.

Medical Director. Blood Assurance is seeking to fill a job opening for **Medical Director** based in our downtown Chattanooga home office. The Medical Director will provide medical and professional guidance to employees of the company and to area medical professionals. Minimum qualifications for consideration include: MD degree required; board certification or eligibility in pathology required (board certification must be secured within 1 year of hire); Transfusion Medicine board certification or eligibility preferred. Must be licensed to practice medicine in the states of our fixed facilities if required by that state (state licensure can be secured after hire). Blood bank management and advanced therapy experience preferred. Success in this will require advanced skills in all of the following areas: verbal and written leadership communications with a servant-leadership philosophy, staff management/development, customer service, conflict resolution, decision-making, strategic planning, collaborative teamwork, flexibility, and adaptability. Proficiency in making Board room presentations and resolving complex medical issues is also required. We offer many benefits including: Health/Dental/Vision Insurance, Flexible Spending Account, Employee Assistance Program for you and your family, Company Paid Time Off, 401K with Company Match, Wellness Program, and Relocation Assistance. Qualified candidates are encouraged to submit an online application for consideration at www.bloodassurance.org. Blood Assurance is an Equal Opportunity Employer and a Tobacco Free Workplace.

Hematology - Quality Control Specialist. Gulf Coast Blood is seeking a Hematology - Quality Control Specialist! This key role supports quality assurance by preparing and testing blood component samples to ensure safety and effectiveness for patients and hospitals throughout the Texas Gulf Coast region. It's ideal for detail-driven individuals who uphold high standards and contribute meaningfully to patient outcomes. Showcase your expertise by performing advanced quality control testing, managing lab operations in the absence of supervisors, and responding to critical situations such as

positive bacterial cultures. You'll initiate recall procedures, track and trend QC results, train new hires, coordinate workflow, and recommend process improvements, all while ensuring compliance with lab standards and supporting patient safety. **Why join us?** We offer a competitive salary, full benefits, free parking at the Texas Medical Center, and opportunities for a sign-on bonus and relocation assistance to support a smooth transition. Enjoy professional development and career advancement opportunities while making a meaningful difference every day. **Qualifications:** MT/MLS certification (ASCP or equivalent) with at least two years of hematology experience. Flow cytometry experience is a plus. This role operates Monday through Friday, 7:00 AM to 3:00 PM. If you embody integrity, commitment, and respect, [apply now](#) and help make a difference!

Assistant Lab Manager, RRPL. Gulf Coast Blood is seeking an Assistant Lab Manager, RRPL! This key role leads operations in the Research and Recovered Product Laboratory, overseeing staff, blood component production, and research products to ensure quality, compliance, and timely delivery. Ideal for organized, detail-driven leaders who uphold high standards and contribute meaningfully to patient care and research. Lead the RRPL team to deliver high-quality blood components and research products while maintaining cGMP, AABB, and FDA compliance. Manage lab operations, optimize workflows, and allocate resources to meet client needs and production goals. Serve as the primary liaison for internal systems, client communications, and quality audits, using data-driven insights to track KPIs and enhance productivity. **Why join us?** Competitive pay, full benefits, career advancement opportunities, and the chance to make a tangible difference in patient outcomes and research. **Qualifications:** Bachelor's in Biology, Chemistry, or related field with three years of lab or blood. Component manufacturing experience (plasma a plus). MT/MLS (ASCP or equivalent) strongly preferred. Minimum two years of supervisory or management experience. Strong knowledge of quality concepts, cGMP, AABB, and FDA regulations. If you embody Commitment, Integrity, and Respect, [apply now](#) to help save lives every day!

Medical Director (Miller-Keystone Blood Center (MKBC)). Are you a mission-driven leader seeking to integrate patient care with public health while improving work-life balance? Join MKBC, where we save lives daily by supplying blood to hospitals across Pennsylvania (PA) and New Jersey (NJ). As **Medical Director**, you'll lead clinical oversight for transfusion medicine and ensure the safety, quality, and regulatory compliance of our blood services. You'll guide donor eligibility, review protocols, supervise lab operations, advise on complex medical issues, and collaborate with hospitals and public health partners. You'll also support staff education, represent MKBC in professional forums, and provide

(continued on page 12)

COMPANY NEWS (continued from page 11)

executive leadership to promote excellence and innovation. **Requirements:** M.D. or D.O. with Board Certification in Clinical Pathology, Internal Medicine, or Hematology. Board Certified or Eligible in Transfusion Medicine. Five to seven plus years in healthcare with a focus in blood banking. Medical licensure in PA & NJ. Strong knowledge of AABB, FDA, CLIA, and cGMP standards. **Benefits include:** Medical/Dental/Vision, FSA, Life Insurance, Disability, PTO, Retirement Plan & more. Make a lasting impact—apply today to join our lifesaving mission and see the full position description here <https://hcsc.isolvedhire.com/jobs/1583606>. 💧